This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Oranje, B. Articles by Kahn, R. S. Search for Related Content PubMed PubMed Citation Articles by Oranje, B. Articles by Kahn, R. S. Social Bookmarking                         What's this?

Increasing Dopaminergic Activity: Effects of L-Dopa and Bromocriptine on Human Sensory Gating

Center for Neuropsychiatric Schizophrenia Research, Department of Psychiatry afd E, Bispebjerg University Hospital, Copenhagen, DenmarkB.Oranje{at}cnsr.dk

C. C. Gispen-de Wied

H. G. M. Westenberg

C. Kemner

Department of Psychiatry, University Medical Center, Utrecht, The Netherlands

M. N. Verbaten

Rudolf Magnus Institute for Neurosciences and Faculty of Pharmaceutical Sciences and Department of Psychopharmacology, Utrecht University, Utrecht, The Netherlands

R. S. Kahn

Department of Psychiatry, University Medical Center, Utrecht, The Netherlands

Schizophrenic patients show a loss of sensory gating, which is reflected in a reduced P50 suppression. Because most of the symptoms inschizophrenia can be reduced by antagonists of the dopaminergic (D₂) system, the loss in sensory gating might be related to an increased dopaminergic activity. Therefore, in the present study, the effects of increased dopaminergic neurotransmisson on sensory gating in healthy volunteers were investigated. In a double-blind, balanced, placebo-controlled design, healthy male volunteers were challenged in twoseparate studies with either 300 mg L-dopa (precursor of dopamine) or placebo (n = 16) and 1.25 mg bromocriptine (D₂ agonist) or placebo (n = 17). Subsequently, they were tested for their sensory gating (P50 suppression). P50 suppression values in the placebo condition werecomparable to those found in literature. Although both L-dopa and bromocriptine reduced P50 amplitude, they did so in an equal ratio for both the response to the conditioning (C) and the testing (T) stimuli, therefore not resulting in a reduction of the P50 suppression ratio (T/C). In the present study, neither L-dopa nor bromocriptine reduced sensory gating in healthy volunteers. This suggests that an increased dopaminergic activity in humans is not responsible for the reduction in sensory gating as seen, for example, in schizophrenia.

Key Words: P50 suppression • bromocriptine • L-dopa • sensory gating

Journal of Psychopharmacology, Vol. 18, No. 3, 388-394 (2004)
DOI: 10.1177/026988110401800310


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Morcom, E. T. Bullmore, F. A. Huppert, B. Lennox, A. Praseedom, H. Linnington, and P. C. Fletcher Memory Encoding and Dopamine in the Aging Brain: A Psychopharmacological Neuroimaging Study Cereb Cortex, July 22, 2009; (2009) bhp139v1. [Abstract] [Full Text] [PDF]

				B. Oranje, C. C. Gispen-de Wied, H. G. M. Westenberg, C. Kemner, M. N. Verbaten, and R. S. Kahn No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention J Psychopharmacol, November 1, 2006; 20(6): 789 - 798. [Abstract] [PDF]